{
    "clinical_study": {
        "@rank": "72351", 
        "arm_group": [
            {
                "arm_group_label": "HBOT", 
                "arm_group_type": "Experimental", 
                "description": "Group will be treated with HBOT for 60 treatments in 3 months."
            }, 
            {
                "arm_group_label": "Control/Crossover", 
                "arm_group_type": "Other", 
                "description": "Control for 3 months without treatment, and then HBOT for 60 treatments in 3 months."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the current study is to evaluate, in a prospective cross-over, randomized study,\n      the effect of hyperbaric oxygen therapy (HBOT) on patients with chronic impairment after low\n      grade glioma tumor removal surgery"
        }, 
        "brief_title": "Hyperbaric Oxygen Therapy Can Improve Cognitive Deficits Post Low Grade Glioma Removal Surgery", 
        "condition": [
            "Post Low Grade Glioma Surgery", 
            "Cognitive Deficits"
        ], 
        "condition_browse": {
            "mesh_term": "Glioma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Post low grade glioma (WHO I-II) removal surgery 3-12 months prior to the inclusion\n             in the study.\n\n          -  All patients have to have persistent cognitive impairment  (Mindstream score should\n             be at least one SD lower than average) regarding without noticeable improvement\n             during the last month prior to their enrolment.\n\n          -  Age 18 years or older.\n\n        Exclusion Criteria:\n\n          -  Dynamic neurologic/cognitive improvement or worsening during the past month; Previous\n             brain radiotherapy and/or radiosurgery. Steroids dependence Chemotherapy in the past\n             month or scheduled in the next 3 months Seizures 1 month previous to inclusion Had\n             been treated with HBOT for any other reason 1 month prior to inclusion; Have any\n             other indication for HBOT; Chest pathology incompatible with pressure changes; Inner\n             ear disease; Patients suffering from claustrophobia; Inability to sign written\n             informed consent; Smoking patients will not be allowed to smoke during the study and\n             if they would not comply with this demand they will be excluded."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "62", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02122042", 
            "org_study_id": "64/14"
        }, 
        "intervention": {
            "arm_group_label": [
                "HBOT", 
                "Control/Crossover"
            ], 
            "intervention_name": "HBOT", 
            "intervention_type": "Biological", 
            "other_name": "HBOT of 2 ATA for 90 minutes O2 100%, for 60 treatments"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 22, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Zerifin", 
                    "country": "Israel", 
                    "zip": "70300"
                }, 
                "name": "Assaf-Harofeh Medical Center"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "Hyperbaric Oxygen Therapy Can Improve Cognitive Deficits Post Low Grade Glioma Removal Surgery - Randomized Prospective Trial", 
        "overall_contact": {
            "email": "amir.had@gmail.com", 
            "last_name": "Amir Hadanny, MD", 
            "phone": "972544707381"
        }, 
        "overall_official": {
            "affiliation": "Assaf-Harofeh Medical Center", 
            "last_name": "Shai Efrati, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Cognitive function will be assessed using the one-hour Mindstreams Computerized Cognitive Test Battery at baseline, 3 months and 6 months to intervention.", 
            "measure": "Neurocognitive functions", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02122042"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Assaf-Harofeh Medical Center", 
            "investigator_full_name": "Assaf Harofeh MC", 
            "investigator_title": "Shai Efrati", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Quality of live will be evaluated by the EQ-5D,SS-QOL \u05d5 SF36 , QLQ-BN20, questionnaires at baseline , 3 months and 6 months to intervention.", 
            "measure": "Quality of Life", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "source": "Assaf-Harofeh Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assaf-Harofeh Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}